Faruqi & Faruqi Investigation: TriVascular Technologies, Inc.
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of TriVascular Technologies, Inc. (“TriVascular” or the “Company”) (NasdaqGS:TRIV) for potential breaches of fiduciary duties in connection with the sale of the Company to Endologix, Inc. for approximately $211 million.
The Company’s stockholders will only receive a combination of cash and stock, to be determined at the closing of the merger, valued at $9.10 for each share of Company common stock they own. However, the offer is lower than at least one analyst’s price target of $13 per share and the April 16, 2014, IPO price of $12 per share.
If you own common stock in TriVascular and wish to obtain additional information and protect your investments free of charge, please contact Juan Monteverde, Esq. either via e-mail at email@example.com or by telephone at (877) 247-4292 or (212) 983-9330.